Date: 2016-08-02
Type of information: Construction of a production plant
Compound: HB6 Plant
Company: Kyowa Hakko Kirin (Japan)
Therapeutic area: Technology - Services
Type agreement: construction of a production plant
Action mechanism:
Disease:
Details: * On August 2, 2016, Kyowa Hakko Kirin announced that the company has completed the construction of the HB6
Plant in the Takasaki Plant (Takasaki city, Gunma, Plant Manager: Hitoshi Arai) in August 2016. The new HB6 facility is equipped with one of the largest bioreactors for recombinant animal cells (12,000 L bioreactor) to produce commercial active pharmaceutical ingredients. The purpose of this facility is to meet the needs of production capacity with the increasing demand of antibody drug and items in the future.The design concept of this facility includes multiproduct production with high productivity to be compliant with the Good Manufacturing Practices (GMP) for Japanese, U.S., and European drug products.
Mainly monoclonal antibody drug substances will be produced, and the products will thus be supplied globally. The facility is planned to start its operations in 2016, and to begin commercial production after 2019.
The plant comprises four stores, with total floor space of approx. 4,000m2. This ¥ 7.1 billion yen plant has been completed in April 2016.
Financial terms:
Latest news:
